丙二醇胺衍生物阳离子脂质体纳米颗粒及其制备方法转让专利
申请号 : CN201110444269.5
文献号 : CN102525926B
文献日 : 2013-04-24
发明人 : 向双林 , 曾佑林 , 张健 , 赵春艳 , 刘珊 , 刘美艳 , 苏胜培 , 曾盈 , 胡翔
申请人 : 湖南师范大学
摘要 :
权利要求 :
1.一种丙二醇胺衍生物阳离子脂质体纳米颗粒,其特征在于该纳米颗粒为碘化2,
3-二烷氧基-1-(N,N,N-三甲基)丙铵或溴化2,3-二烷氧基-1-(N,N-二甲基-N-(2-羟乙基))丙铵,纳米颗粒平均粒径为60-220nm,PDI分布值为0.277-0.456,Zeta表面电势为40-60mv,pH值为5.4-5.8,所述烷氧基为正辛烷氧基、正十二烷氧基、正十四烷氧基、正十六烷氧基、正十八烷氧基。
2.一种根据权利要求1所述丙二醇胺衍生物阳离子脂质体纳米颗粒的制备方法,其特征在于该制备方法包括如下步骤:(1)以环氧氯丙烷为原料,以一水合对甲基苯磺酸为催化剂,水为溶剂及反应物,回流水解开环,经柱层析分离纯化得到无色液体3-氯-1,2-丙二醇;
(2)在氢氧化钠存在下,步骤(1)所获得的无色液体3-氯-1,2-丙二醇与N,N-二甲胺盐酸盐进行叔胺化反应,经柱层析分离纯化处理得到黄色液体3-(N,N-二甲基胺基)-1,
2-丙二醇;
(3)以四氢呋喃为溶剂,以氢化钠为催化剂,3-(N,N-二甲基胺基)-1,2-丙二醇与烷基溴回流反应,经柱层析分离纯化处理得到2,3-二烷氧基-1-(N,N-二甲基)丙胺;
(4)步骤(3)得到的2,3-二烷氧基-1-(N,N-二甲基)丙胺与碘甲烷进行季铵盐化反应,经乙酸乙酯重结晶纯化处理得白色固体,经超声波振荡水分散后得到相应的丙二醇胺衍生物阳离子脂质体TMA-Apd纳米颗粒。
3.一种根据权利要求1所述丙二醇胺衍生物阳离子脂质体纳米颗粒的制备方法,其特征在于该制备方法包括如下步骤:(1)以环氧氯丙烷为原料,以一水合对甲基苯磺酸为催化剂,水为溶剂及反应物,回流水解开环,经柱层析分离纯化得到无色液体3-氯-1,2-丙二醇;
(2)在氢氧化钠存在下,步骤(1)所获得的无色液体3-氯-1,2-丙二醇与N,N-二甲胺盐酸盐进行叔胺化反应,经柱层析分离纯化处理得到黄色液体3-(N,N-二甲基胺基)-1,
2-丙二醇;
(3)以四氢呋喃为溶剂,以氢化钠为催化剂,3-(N,N-二甲基胺基)-1,2-丙二醇与烷基溴回流反应,经柱层析分离纯化处理得到2,3-二烷氧基-1-(N,N-二甲基)丙胺;
(4)步骤(3)得到的2,3-二烷氧基-1-(N,N-二甲基)丙胺与1-溴乙醇进行季铵盐化反应,经乙酸乙酯重结晶纯化处理得白色固体,经超声波振荡水分散后得到丙二醇胺衍生物阳离子脂质体HEDMA-Apd纳米颗粒。
4.根据权利要求2或3所述丙二醇胺衍生物阳离子脂质体纳米颗粒的制备方法,其特征在于:所述步骤(1)的投料比为摩尔比1:0.002:4.3的环氧氯丙烷:一水合对甲基苯磺酸:水;100℃回流反应6h,浓缩,柱层析分离洗脱剂为体积比2:1的石油醚:乙酸乙酯,制得3-氯-1,2-丙二醇。
5.根据权利要求2或3所述丙二醇胺衍生物阳离子脂质体纳米颗粒的制备方法,其特征在于:所述步骤(2)的投料比为摩尔比1:5.5:5.5的3-氯-1,2-丙二醇:N,N-二甲胺盐酸盐:氢氧化钠;常温搅拌反应12h,柱层析分离洗脱剂为体积比10:1的乙酸乙酯:甲醇,纯化得到黄色液体3-(N,N-二甲基胺基)-1,2-丙二醇。
6.根据权利要求2或3所述丙二醇胺衍生物阳离子脂质体纳米颗粒的制备方法,其特征在于:所述步骤(3)的投料比为摩尔比1:2:4的3-(N,N-二甲基胺基)-1,2-丙二醇:氢化钠:烷基溴;以四氢呋喃为溶剂,65°C回流24h,柱层析分离洗脱剂为体积比1:1的乙酸乙酯:石油醚,得黄色液体2,3-二烷氧基-1-(N,N-二甲基)丙胺,所述烷基溴为正辛基溴、正十二烷基溴、正十四烷基溴、正十六烷基溴、正十八烷基溴。
7.根据权利要求2所述丙二醇胺衍生物阳离子脂质体纳米颗粒的制备方法,其特征在于:所述步骤(4)的投料比为摩尔比1:10的2,3-二烷氧基-1-(N,N-二甲基)丙胺:碘甲烷;以乙腈为溶剂,81℃回流15h,经乙酸乙酯重结晶得白色固体碘化2,3-二烷氧基-1-(N,N,N-三甲基)丙铵,超声波振荡水分散后得到阳离子脂质体TMA-Apd纳米颗粒。
8.根据权利要求3所述丙二醇胺衍生物阳离子脂质体纳米颗粒的制备方法,其特征在于:所述步骤(4)的投料比为摩尔比1:5的2,3-二烷氧基-1-(N,N-二甲基)丙胺:1-溴乙醇;以乙腈为溶剂,81℃回流12h,经乙酸乙酯重结晶得白色固体溴化2,3-二烷氧基-1-(N,N-二甲基-N-(2-羟乙基))丙铵,超声波振荡水分散后得到阳离子脂质体HEDMA-Apd纳米颗粒。
9.根据权利要求7或8所述丙二醇胺衍生物阳离子脂质体纳米颗粒的制备方法,其特征在于所述乙腈用量为:1g2,3-二烷氧基-1-(N,N-二甲基)丙胺使用20ml乙腈,不足1g按1g计。
说明书 :
丙二醇胺衍生物阳离子脂质体纳米颗粒及其制备方法
技术领域
背景技术
发明内容
附图说明
具体实施方式
1
13
3.64-3.55(m,3H,-CH2Cl and-CHHOH); C NMR(125MHz,CDCl3),(ppm):71.7(1C,-CHOH),
63.6(1C,-CH2OH),45.7(1C,-CH2Cl)。
13
8H,-CH2N(CH3)2and N(CH3)2); C NMR(125MHz,CDCl3):68.3(1C,-CHOH),65.1(1C,-CH2OH),
62.1(1C,-CH2N(CH3)2),45.6(2C,-N(CH3)2).
2H,-CH2N(CH3)2),2.25(s,6H,-CH2N(CH3)2),1.55-1.50(m,4H,2-OCH2CH2(CH2)9CH3),
13
1.25-1.20(m,36H,2-OCH2CH2(CH2)9CH3),0.87(t,6H,J=7.0Hz,2-OCH2CH2(CH2)9CH3); C NMR(125MHz,CDCl3):82.73(1C,-CHCH2N(CH3)2),72.4(1C,-CH2CHCH2N(CH3)2),71.8,
70.5(2C,2-OCH2CH2(CH2)9CH3),61.4(1C,-CH2CHCH2N(CH3)2),46.6(2C,-CH2CHCH2N(CH3)2),
32.2,30.5,30.0,29.9,29.8,29.6,26.4(18C,some signals were overlapped,
2-OCH2CH2(CH2)9CH3),22.9(2C,2-OCH2CH2(CH2)9CH3),14.4(2C,2-OCH2CH2(CH2)9CH3).[0035] 向50mL圆底烧瓶中加入2,3-二正十二烷氧基-1-(N,N-二甲基)丙胺(1.0g,
2.2mmol)和乙腈(20mL)。搅拌下滴加碘甲烷(3.1g,21.8mmol),回流15h。TLC(乙酸乙酯)检测,原料基本反应完全。浓缩,得黄色固体,用乙酸乙酯溶解,冷却至室温,有白色固体析出,过滤,得白色固体碘化2,3-二正十二烷氧基-1-(N,N,N-三甲基)丙铵
3.56(s,9H,-CH2CHCH2N(CH3)3),1.56-1.52(m,4H,2-OCH2CH2(CH2)9CH3),1.25-1.18(m,
13
36H,2-OCH2CH2(CH2)9CH3),0.87(t,6H,J=7.0Hz,2-OCH2CH2(CH2)9CH3); C NMR(125MHz,+ +
CDCl3):73.7(1C,-CHCH2N (CH3)3),72.2(1C,-CH2CHCH2N (CH3)3),69.4,68.2(2C,+ +
2-OCH2CH2(CH2)9CH3),61.2(1C,-CH2N(CH3)3),55.4(3C,-N(CH3)3),32.1,30.1,29.8,29.7,
29.6,29.5,26.4,26.2(18C,some signals were overlapped,2-OCH2(CH2)9CH2CH3),22.8,
22.8(2C,2-OCH2(CH2)9CH2CH3),14.3(2C,2-OCH2CH2(CH2)9CH3)。
4.17-4.16(m,2H,-CH2CH2OH),4.08-4.06(m,1H,-CHCH2N(CH3)2CH2CH2OH),3.91-3.87(m,+ +
2H,-CH2CHCH2N(CH3)2CH2CH2OH),3.80-3.69(m,2H,-CH2N(CH3)2CH2CH2OH),3.56-3.53(m,+
2H,-CH2CH2OH),3.50-3.33(m,10H,-N(CH3)2CH2CH2OH,2-OCH2CH2(CH2)9CH3),1.55-1.53(m,
4H,2-OCH2CH2(CH2)9CH3),1.25-1.24(m,36H,2-OCH2CH2(CH2)9CH3),0.87(t,6H,J=7.0Hz,
13 +
2-OCH2(CH2)9CH2CH3); C NMR(125MHz,CDCl3):73.6(1C,-CH2CHCH2N (CH3)2CH2CH2OH),+ +
72.3(1C,-CHCH2N(CH3)2CH2CH2OH),69.6(1C,-CH2N(CH3)2CH2CH2OH),68.9(1C,-CH2CH2OH),+
67.6(1C,-CH2CHCH2N (CH3)2CH2CH2OH),67.3,67.3(2C,2-OCH2CH2(CH2)9CH3),+
56.2(1C,-CH2CH2OH),54.0,53.5(2C,-N(CH3)2CH2CH2OH),32.1,30.2,29.9,29.8,29.7,
29.6,26.4,26.3(18C,some signals were overlapped,2-OCH2(CH2)9CH2CH3),22.9,(2C,
2-OCH2(CH2)9CH2CH3),14.3(2C,2-OCH2(CH2)9CH2CH3).
40.8mmol),回流24h。TLC(乙酸乙酯)检测,原料基本反应完全。浓缩,用水和乙酸乙酯萃取,有机相用无水硫酸钠干燥,过滤,浓缩。残留物经柱层析(洗脱剂:石油醚:乙酸乙酯=1:
1)分离,得亮黄色液体2,3-二正辛烷氧基-1-(N,N-二甲基)丙胺
2H,-CH2N(CH3)2),2.24(s,6H,-CH2N(CH3)2),1.55-1.53(m,4H,2-OCH2CH2(CH2)5CH3),
13
1.34-1.17(m,20H,2-OCH2CH2(CH2)5CH3),0.86(t,6H,J=7.0Hz,2-OCH2CH2(CH2)5CH3); C NMR(125MHz,CDCl3):82.73(1C,-CHCH2N(CH3)2),72.1(1C,-CH2CHCH2N(CH3)2),71.6,
71.5(2C,2-OCH2CH2(CH2)5CH3),61.1(1C,-CH2CHCH2N(CH3)2),46.3(2C,-CH2CHCH2N(CH3)2),
31.8,30.1,29.6,29.4,29.3,26.1(10C,some signals were overlapped,
2-OCH2(CH2)5CH2CH3),22.6(2C,2-OCH2(CH2)5CH2CH3),14.0(2C,2-OCH2CH2(CH2)5CH3).[0045] 向50mL圆底烧瓶中加入2,3-二正辛烷氧基-1-(N,N-二甲基)丙胺(1.1g,
3.2mmol)和乙腈(20mL)。搅拌下滴加碘甲烷(4.5g,32.0mmol),回流15h。TLC(乙酸乙酯)检测,原料基本反应完全。浓缩,得橘黄色液体。经柱层析(洗脱剂:乙酸乙酯:甲醇=5:1)分离,得白色固体碘化2,3-二正辛烷氧基-1-(N,N,N-三甲基)丙铵
1 +
(0.8g,1.6mmol,50.0%)。H NMR(500MHz,CDCl3),(ppm):4.08-3.97(m,2H,-CHCH2N(CH+ + +
3)3and-CHCHHN(CH3)3),3.67-3.39(m,16H,-CHCHHN(CH3)3,-CH2CHCH2N(CH3)3),-CH2CHCH+
2N(CH3)3)and2-OCH2CH2(CH2)5CH3),1.54-1.50(m,4H,2-OCH2CH2(CH2)5CH3),1.25-1.23(m,
13
20H,2-OCH2CH2(CH2)5CH3),0.84(t,6H,J=7.0Hz,2-OCH2CH2(CH2)5CH3); C NMR(125MHz,+ +
CDCl3):73.6(1C,-CHCH2N(C H3)3),72.2(1C,-CH2CHCH2N (CH3)3),69.4,68.2(2C,+ +
2-OCH2CH2(CH2)5CH3),61.2(1C,-CH2N(CH3)3),55.3(3C,-N(CH3)3),31.9,31.8,30.1,29.5,
29.4,29.3,29.2,26.2,26.1(10C,some signals were overlapped,2-OCH2(CH2)5CH2CH3),
22.8,22.7(2C,2-OCH2(CH2)5CH2CH3),14.2,14.2(2C,2-OCH2(CH2)5CH2CH3)。
1
乙 基 )) 丙 铵 (0.7g,1.5mmol,46.9%)。H NMR(500MHz,CDCl3),(ppm):5.03(br,+
1H,-CH2CH2OH),4.17-4.16(m,2H,-CH2CH2OH),4.08-4.06(m,1H,-CHCH2N(CH3)2CH2CH2OH),+ +
3.91-3.87(m,2H,-CH2CHCH2N(CH3)2CH2CH2OH),3.80-3.69(m,2H,-CH2N(CH3)2CH2CH2OH),+
3.56-3.53(m,2H,-CH2CH2OH),3.50-3.33(m,10H,-N(CH3)2CH2CH2OH,2-OCH2CH2(CH2)5CH3),
1.55-1.53(m,4H,2-OCH2CH2(CH2)5CH3),1.25-1.24(m,20H,2-OCH2CH2(CH2)5CH3),0.87(t,6H,
13 +
J=2.5Hz,2-OCH2(CH2)6CH3); C NMR(125MHz,CDCl3):73.6(1C,-CHCH2N(CH3)2CH2CH2OH),+ +
69.6(1C,-CH2N(CH3)2CH2CH2OH),72.3(1C,-CHCH2N(CH3)2CH2CH2OH),68.9(1C,-CH2CH2OH),6+
7.6(1C,-CH2CHCH2N(CH3)2CH2CH2OH),67.3,67.3(2C,2-OCH2(CH2)6CH3),56.2(1C,-CH2CH2OH),+
54.0,53.5(2C,-N (CH3)2CH2CH2OH),32.1,30.2,29.9,29.8,29.7,29.6,26.4,26.3,
22.9(12C,2-OCH2(CH2)6CH3),14.1,14.1(2C,2-OCH2(CH2)6CH3).
1
3.7mmol,23.3%)。H NMR(500MHz,CDCl3),(ppm):3.57-3.40(m,7H,-CHCH2N(CH3)2),2-OCH2CH
2(CH2)11CH3and-CH2CHCH2N(CH3)2),2.40-2.31(m,2H,-CH2N(CH3)2),2.23(s,6H,-CH2N(CH3)2),
1.55-1.50(m,4H,2-OCH2CH2(CH2)11CH3),1.37-1.16(m,44H,2-OCH2CH2(CH2)11CH3),
13
0.87(t,6H,J=7.0Hz,2-OCH2CH2(CH2)11CH3); C NMR(125MHz,CDCl3):72.3,72.3(2C,
2-OCH2CH2(CH2)11CH3),71.7(1C,-CH2CHCH2N(CH3)2),70.4(1C,-CHCH2N(CH3)2),
61.3(1C,-CH2CHCH2N(CH3)2),46.5(2C,-CH2CHCH2N(CH3)2),32.1,30.4,29.9,29.8,29.7,
29.6,26.3,(22C,some signals were overlapped,2-OCH2(CH2)11CH2CH3),22.9(2C,
2-OCH2(CH2)11CH2CH3),14.3,14.3(2C,2-OCH2CH2(CH2)11CH3).
3),-CH2CHCH2N(CH3)3)and2-OCH2CH2(CH2)11CH3),1.57-1.54(m,4H,2-OCH2CH2(CH2)11CH3),
13
1.34-1.13(m,44H,2-OCH2CH2(CH2)11CH3),0.87(t,6H,J=7.0Hz,2-OCH2CH2(CH2)11CH3); C + +
NMR(125MHz,CDCl3):73.6(1C,-CHCH2N (CH3)3),72.2(1C,-CH2CHCH2N(CH3)3),69.4,+ +
68.2(2C,2-OCH2CH2(CH2)11CH3),61.2(1C,-CHHN(CH3)3),55.4(3C,-N(CH3)3),32.1,30.1,
29.8,29.6,29.5,26.4,26.2(22C,some signals were overlapped,2-OCH2(CH2)11CH2CH3),
22.8,22.8(2C,2-OCH2(CH2)11CH2CH3),14.3,14.3(2C,2-OCH2CH2(CH2)11CH3)。
4.21-4.06(m,2H,-CH2CH2OH),4.20-4.07(m,1H,-CHCH2N(CH3)2CH2CH2OH),3.93-3.85(m,+ +
2H,-CH2CHCH2N(CH3)2CH2CH2OH),3.85-3.78(m,2H,-CH2N(CH3)2CH2CH2OH),3.61-3.51(m,+
2H,-CH2CH2OH),3.51-3.49(m,10H,-N(CH3)2CH2CH2OH,2-OCH2CH2(CH2)11CH3),1.56-1.54(m,
4H,2-OCH2CH2(CH2)11CH3),1.32-1.16(m,44H,2-OCH2CH2(CH2)11CH3),0.87(t,6H,J=7.0Hz,
13 +
2-OCH2(CH2)11CH2CH3); C NMR(125MHz,CDCl3):73.5(1C,-CHCH2N(CH3)2CH2CH2OH),+ +
72.2(1C,-CHCH2N(CH3)2CH2CH2OH),69.5(1C,-CH2N(CH3)2CH2CH2OH),68.7(1C,-CH2CH2OH),+
67.5(1C,-CH2CHCH2N (CH3)2CH2CH2OH),67.5,67.2(2C,2-OCH2CH2(CH2)11CH3),+
56.1(1C,-CH2CH2OH),53.9,53.4(2C,-N(CH3)2CH2CH2OH),32.1,30.2,29.9,29.8,29.7,
29.6,26.4,26.3,22.9,(22C,some signals were overlapped,2-OCH2(CH2)11CH2CH3),22.8,
21.1(2C,2-OCH2(CH2)11CH2CH3),14.1,14.1(2C,2-OCH2(CH2)12CH3).
2H,-CH2N(CH3)2),2.25(s,6H,-CH2N(CH3)2),1.55-1.50(m,4H,2-OCH2CH2(CH2)13CH3),
13
1.31-1.20(m,52H,2-OCH2CH2(CH2)13CH3),0.87(t,6H,J=7.0Hz,2-OCH2CH2(CH2)13CH3); CNMR(125MHz,CDCl3):85.9(1C,-CHCH2N(CH3)2),72.3(1C,-CH2CHCH2N(CH3)2),71.8,70.4(2C,
2-OCH2CH2(CH2)13CH3),61.3(1C,-CH2CHCH2N(CH3)2),46.5,46.5(2C,-CH2CHCH2N(CH3)2),
32.1,30.4,30.2,29.9,29.7,29.6,26.3,26.2,(26C,some signals were overlapped,
2-OCH2(CH2)14CH3),22.9(2C,2-OCH2(CH2)13CH2CH3),14.3,14.3,(2C,2-OCH2(CH2)14CH3).[0062] 向50mL圆底烧瓶中加入2,3-二正十六烷氧基-1-(N,N-二甲基)丙胺(0.7g,
1.2mmol)和乙腈(20mL)。搅拌下滴加碘甲烷(1.7g,12mmol),回流15h。TLC(乙酸乙酯)检测,原料基本反应完全。浓缩,得黄色固体,用乙酸乙酯溶解,冷却至室温,有白色固体析出,过滤,得白色固体碘化2,3-二正十六烷氧基-1-(N,N,N-三甲基)丙铵
1 +
(0.7g,1.0mmol,83.3%)。H NMR(500MHz,CDCl3),(ppm):4.09-4.04(m,2H,-CHCH2N(CH3+ + +
)3and-CHCHHN(CH3)3),3.68-3.38(m,16H,-CHCHHN(CH3)3,-CH2CHCH2N(CH3)3),-CH2CHCH2+
N(CH3)3)and2-OCH2CH2(CH2)13CH3),1.57-1.52(m,4H,2-OCH2CH2(CH2)13CH3),1.33-1.21(m,
13
52H,2-OCH2CH2(CH2)13CH3),0.86(t,6H,J=7.0Hz,2-OCH2CH2(CH2)13CH3); C NMR(125MHz,+ +
CDCl3):73.6(1C,-CHCH2N(CH3)3),72.1,72.2,69.3(3C,-CH2CHCH2N(CH3)3and2-OCH2CH2(CH+ +
2)13CH3),68.2(1C,-CHHN(CH3)3),55.4(3C,-N(CH3)3),32.1,30.1,29.9,29.8,29.7,29.6,
29.5,26.4,26.2(26C,some signals were overlapped,2-OCH2(CH2)13CH2CH3),22.8(2C,
2-OCH2(CH2)13CH2CH3),14.3,14.3(2C,2-OCH2(CH2)13CH2CH3)。
1
丙 铵 (0.8g,1.2mmol,75.0%)。H NMR(500MHz,CDCl3),(ppm):5.00(br,1H,-CH2CH2OH),+
4.13-4.09(m,2H,-CH2CH2OH),4.09-4.03(m,1H,-CHCH2N(CH3)2CH2CH2OH),3.92-3.82(m,+ +
2H,-CH2CHCH2N(CH3)2CH2CH2OH),3.82-3.74(m,2H,-CH2N(CH3)2CH2CH2OH),3.56-3.53(m,+
2H,-CH2CH2OH),3.49-3.35(m,10H,-N(CH3)2CH2CH2OH,2-OCH2CH2(CH2)13CH3),1.58-1.42(m,
4H,2-OCH2CH2(CH2)13CH3),1.31-1.12(m,52H,2-OCH2CH2(CH2)13CH3),0.85(t,6H,J=7.0Hz,
13 +
2-OCH2(CH2)13CH2CH3); C NMR(125MHz,CDCl3):73.5(1C,-CHCH2N(CH3)2CH2CH2OH),+ +
72.2(1C,-CHCH2N(CH3)2CH2CH2OH),69.5(1C,-CH2N(CH3)2CH2CH2OH),68.8(1C,-CH2CH2OH),+
67.5(1C,-CH2CHCH2N (CH3)2CH2CH2OH),67.3,67.2(2C,2-OCH2CH2(CH2)13CH3),+
56.2(1C,-CH2CH2OH),53.9,53.5(2C,-N(CH3)2CH2CH2OH),32.1,30.1,29.9,29.8,29.7,
29.6,26.4,26.3,22.9,(26C,some signals were overlapped,2-OCH2(CH2)13CH2CH3),
22.8(2C,2-OCH2(CH2)13CH2CH3),14.2,14.2(2C,2-OCH2(CH2)10CH3).
1
18.5%)。H NMR(500MHz,CDCl3),(ppm):3.60-3.41(m,7H,-CHCH2N(CH3)2),2-OCH2CH2(CH2)15CH3and-CH2CHCH2N(CH3)2),2.42-2.33(m,2H,-CH2N(CH3)2),2.25(s,6H,-CH2N(CH3)2),
1.57-1.53(m,4H,2-OCH2CH2(CH2)15CH3),1.35-1.11(m,60H,2-OCH2CH2(CH2)15CH3),0.87(t,
13
6H,J=7.0Hz,2-OCH2CH2(CH2)15CH3); C NMR(125MHz,CDCl3):72.4,71.8,71.8,70.4(4C,-CH2CHCH2N(CH3)2),-CH2CHCH2N(CH3)2)and2-OCH2CH2(CH2)15CH3),61.3(1C,-CH2CHCH2N(CH3)2),
46.6(2C,-CH2CHCH2N(CH3)2),32.1,30.4,29.9,29.8,29.7,29.6,29.5,27.1,26.3,(30C,some signals were overlapped,2-OCH2(CH2)15CH2CH3),22.9(2C,2-OCH2(CH2)15CH2CH3),
14.3,14.3(2C,2-OCH2CH2(CH2)15CH3).
CH2N(CH3)3)and2-OCH2CH2(CH2)15CH3),1.56-1.52(m,4H,2-OCH2CH2(CH2)15CH3),1.32-1.20(m,
13
60H,2-OCH2CH2(CH2)15CH3),0.87(t,6H,J=7.0Hz,2-OCH2CH2(CH2)15CH3); C NMR(125MHz,+ +
CDCl3):73.6(1C,-CHCH2N(CH3)3),72.2,72.2,69.4(3C,-CH2CHCH2N(CH3)3and2-OCH2CH2(CH+ +
2)15CH3),68.2(1C,-CHHN(CH3)3),55.4(3C,-N(CH3)3),32.1,30.1,29.9,29.8,29.7,29.6,
29.5,26.4,26.2(30C,some signals were overlapped,2-OCH2(CH2)15CH2CH3),22.8,(2C,
2-OCH2(CH2)15CH2CH3),14.3,14.3(2C,2-OCH2(CH2)15CH2CH3)。
4.20-4.15(m,2H,-CH2CH2OH),4.08-4.06(m,1H,-CHCH2N(CH3)2CH2CH2OH),3.92-3.84(m,+ +
2H,-CH2CHCH2N(CH3)2CH2CH2OH),3.80-3.69(m,2H,-CH2N(CH3)2CH2CH2OH),3.69-3.48(m,+
2H,-CH2CH2OH),3.46-3.39(m,10H,-N(CH3)2CH2CH2OH,2-OCH2CH2(CH2)15CH3),1.58-1.45(m,
4H,2-OCH2CH2(CH2)15CH3),1.30-1.09(m,36H,2-OCH2CH2(CH2)15CH3),0.86(t,6H,J=7.0Hz,
13 +
2-OCH2(CH2)15CH2CH3); C NMR(125MHz,CDCl3):73.5(1C,-CHCH2N(CH3)2CH2CH2OH),+ +
72.2(1C,-CHCH2N(CH3)2CH2CH2OH),69.6(1C,-CH2N(CH3)2CH2CH2OH),68.7(1C,-CH2CH2OH),+
67.6(1C,-CH2CHCH2N (CH3)2CH2CH2OH),67.3,60.5(2C,2-OCH2CH2(CH2)15CH3),+
56.2(1C,-CH2CH2OH),54.0,53.5(2C,-N(CH3)2CH2CH2OH),32.1,30.1,29.9,29.8,29.7,
29.6,29.5,26.4,26.3,26.2(30C,some signals were overlapped,2-OCH2(CH2)15CH2CH3),
22.8,21.2(2C,2-OCH2(CH2)15CH2CH3),14.3,14.2(2C,2-OCH2(CH2)15CH3).